Clinical Trials Arena on MSN1d
J&J’s NSCLC combo projected to extend survival by one year over TagrissoRybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combination therapy is projected to increase overall survival (OS) by ...
Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...
Nevertheless, it is a setback for J&J. The current intravenous formulation of Rybrevant has picked up four FDA approvals in previously untreated and relapsed/refractory EGFR-mutated NSCLC - as a ...
The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...
The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...
Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line ...
GlobalData forecasts combined sales of $4.1bn for Lazcluze and Rybrevant by 2030. The recent approvals in both Europe and the US, where the combination was approved by the US Food and Drug ...
The drug has been authorised for use alongside J&J’s approved cancer drug Rybrevant (amivantamab) to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and ...
Johnson & Johnson (NYSE:JNJ) experienced an 11% price increase over the last quarter. This movement coincided with several ...
The drug has been authorised for use alongside J&J’s approved cancer drug Rybrevant (amivantamab) to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback